Humacyte Plunges After Deeply Discounted $50M Offering; Strong Phase 3 Data Provides Limited Cushion
Humacyte shares tumbled after the company priced a $50 million underwritten offering at $1.05 per share, matching the market price and signaling substantial dilution. The move came alongside positive interim top-line Phase 3 results from the V012 study presented at a vascular surgery meeting, but investors focused on the financing amid a going-conc…